Engineered immune cells take aim at lingering colorectal cancer
NCT ID NCT06358430
First seen Nov 19, 2025 · Last updated Jun 14, 2026 · Updated 30 times
Summary
This early-phase trial tests a new combination treatment for people with colorectal cancer who have minimal residual disease (MRD) — tiny amounts of cancer left after standard therapy. The treatment uses specially engineered natural killer (NK) cells from donated cord blood, designed to target a protein called TROP2 on cancer cells, plus a drug called cetuximab. The main goal is to find the safest dose and check for side effects in about 42 adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.